Harvard University’s Office of Technology Development said this week that it has appointed Curtis Keith as chief scientific officer for the Accelerator Fund.
Keith will manage the life science R&D projects supported by the Accelerator, including ensuring that funded projects stay on course and meet development milestones. He joins Harvard’s OTD from CombinatoRx, where he served as co-founder and senior vice president of research. He obtained a PhD in chemistry and chemical biology and an MA in chemistry from Harvard, and holds a BS in biochemistry from McGill University.
Dave Tapolczay has been named the new director of MRC Technology, the tech-transfer company of the UK Medical Research Council.
Tapolczay previously worked as vice president of technology development at GlaxoSmithKline Pharmaceuticals, and has also served as CEO of StylaCats and Pharmophix.